PDF Archive

CANCER CORE EUROPE ANNUAL MEETING - Tuesday January 31st - Wednesday February 1st
Communication Center of the DKFZ - Im Neuenheimer Feld 280, D-69121 Heidelberg

9:30 AM - 5 PM

9:50 AM

DAY 1 - TUESDAY, JAN 31st
Task Force Working Groups (AM) - Scientific talks (PM)
REGISTRATION
Luggage and Coats can be stored in the foyer, in front of the Lecture Hall

10:00 - 11:30 AM

Welcome and introductory remarks
TASK FORCE WORKING GROUPS
Parallel sessions
Rooms : D0.01.021 / D0.02.07 and Seminar Rooms 1 & 2 - Marsilius Kolleg building

11:30 AM - 1:00 PM

TASK FORCE UPDATES
Lecture Hall

11:30
11:45
12:00
12:15
12:30
12:45

Clinical Trials
Immuno-oncology
Genomics
Imaging
Data Sharing
Training & Education

1 PM - 2 PM

Lunch Break

2 PM - 4:40 PM

Scientific Talks

02:00
02:20 - 4:15 PM
02:20
02:35
2:50 - 3:05 PM
03:05
03:20
03:40
4:00 - 4:15 PM
4:15 PM

Michael Baumann (DKFZ) Personalized Approaches in Radiation Oncology
SESSION 1: From Genomics to the Clinic
Ana Vivancos (VHIO) TBC
Janne Lehtio (KI) Cancer Proteomics - complementing genotype with molecular phenotype
Discussion
Stefan Pfister (DKFZ) Molecular brain tumor classification - from bench to bedside
René Bernards (NKI) Science-driven personalized medicine beyond simple genotyping
Olli Kallioniemi (KI) Systems medicine to guide cancer treatment decisions and drug development 
Discussion
Lukas Amler - Roche-Genentech Exploring and understanding patient heterogeneity for treatment with checkpoint inhibitors
Cocktail reception following the scientific program

08:30 AM - 4:15 PM
08:30
08:40
8:50 - 10:15 AM
08:50
09:10
09:30
09:45

DAY 2 - WEDNESDAY, FEB 1st
SCIENTIFIC TALKS - all talks will be held in the Lecture Hall
Short talk - CCC
Radiomics of primary staging diffusion-weighted MRI to predict neoadjuvant treatment response in
Short talk - Joost van Griethuysen (NKI)
rectal cancer
SESSION 2: Infrastructures and Experimental Models for Better Outcomes
David Tamborero (VHIO) Interpreting the biological and clinical relevance of cancer variants
A biobank of breast cancer PDTXs with preserved intra-tumor heterogeneity to screen anticancer
Alejandra Bruna (CCC)
compounds
Daniel Vis (NKI) TBC
Short talk - Martin Lablans (DKFZ) Data Exchange with Bridgeheads: Report from the German Cancer Consortium

09:55 - 10:10 AM

Discussion

10:10 - 10:25

Coffee Break

10:25 - 12:00
10:25
10:45
11:00
11:15
11:30
11:40 - 12:00 AM
12:00

SESSION 3: Monitoring Patient Response to Therapy
TBC
Computational medical imaging to characterize key oncogenetic processes
Structural and Functional Imaging of tumours and response to treatment
Developments in neo-adjuvant & adjuvant treatment of melanoma
The Karolinska prostate cancer liquid biopsy program
Discussion
AstraZeneca speaker TBD

Duncan Jodrell (CCC)
Charles Ferté (GR)
Ferdia Gallagher (CCC)
Alexander van Akkooi (NKI)
Short talk - Johan Lindberg (KI)

12:30 - 1:30 PM
1:30 - 2:20 PM
01:30
01:45
02:00
2:10 - 2:20 PM
2:20 PM
02:50 - 4:00 PM
02:50
03:05
03:20
03:35
3:45 - 4:00 PM
4 - 4:15 PM
4:15 PM

Lunch Break
SESSION 4: Innovation in Immunotherapy Clinical Trials
Sandrine Aspeslagh (GR) TBC
Dirk Jäger (DKFZ) Understanding response and resistance as endpoints of clinical trials
Short talk - Alena Gros (VHIO) Neoantigen specific lymphocytes in liquid biopsies
Discussion
Thomas Hudson - AbbVie TBC

Christophe Massard (GR)
Simon Ekman (KI)
Irene Braña (VHIO)
Short talk - Yohann Loriot (GR)

SESSION 5: Improving the Impact of Clinical Trials
Molecular screening in phase 1 trials
TBC
TBC
TBC
Discussion
CLOSING REMARKS
Departure